Skip to content

Study · Systematic review · n = 231 · 2026

3 results

Weight Loss Medications for Adult Patients With Obesity and Binge Eating-A Systematic Review and Meta-analysis.

Violante-Cumpa JR, Rios-Ortega AG, Sánchez-García A, Treviño-Alvarez AM, González-Cruz DC, Manzanares-Gallegos DM, Gutiérrez-Dávila LF, Moreno-Alvarado M, Montelongo-Cepeda JE, de Las Fuentes-Cepeda A, Santos-Santillana AA, Guzman-Cisneros D, González-González JG, Mancillas-Adame LG, Rodríguez-Gutiérrez R

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists7 Jan 2026

PMID41513086 (opens in a new tab)DOI10.1016/j.eprac.2025.11.002 (opens in a new tab)PepBankPUB-41513086
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with obesity and binge eating, liraglutide showed greater weight loss in the meta-analysis.

    In plain wordsIn adults with obesity and binge eating, liraglutide produced greater weight loss.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss
    Study

    n = 231

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight loss
    −4.95 kg
    liraglutide

    Source sentences

    Summary
    Liraglutide (n = 231) showed a greater weight loss (-4.95 kg [-7.12, -2.77]) and a reduction in BE episodes in most individual studies but did not reach statistical significance in the meta-analysis.
    1 context sentence
    Summary · context
    Eight randomized controlled trials (870 participants) were included. Most participants were women (>63%), mean age 45 years, body mass index 35 to 40 kg/m2.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with obesity and binge eating, liraglutide reduced binge eating episodes in most individual studies.

    In plain wordsIn adults with obesity and binge eating, liraglutide reduced binge eating episodes in most individual studies.

    Peptide
    Liraglutide
    Outcome
    DecreaseBinge eating episodes in individual studies
    Study

    n = 231

    Outcome group
    Appetite and food intake · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide (n = 231) showed a greater weight loss (-4.95 kg [-7.12, -2.77]) and a reduction in BE episodes in most individual studies but did not reach statistical significance in the meta-analysis.
    1 context sentence
    Summary · context
    Eight randomized controlled trials (870 participants) were included. Most participants were women (>63%), mean age 45 years, body mass index 35 to 40 kg/m2.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with obesity and binge eating, the liraglutide reduction in binge eating episodes did not reach statistical significance in the meta-analysis.

    In plain wordsIn adults with obesity and binge eating, liraglutide did not significantly reduce binge eating episodes in the meta-analysis.

    Peptide
    Liraglutide
    Outcome
    No significant changeBinge eating episodes in meta-analysis
    Study

    n = 231

    Outcome group
    Appetite and food intake · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide (n = 231) showed a greater weight loss (-4.95 kg [-7.12, -2.77]) and a reduction in BE episodes in most individual studies but did not reach statistical significance in the meta-analysis.
    1 context sentence
    Summary · context
    Eight randomized controlled trials (870 participants) were included. Most participants were women (>63%), mean age 45 years, body mass index 35 to 40 kg/m2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.